Cathelicidin-expressing lactic acid bacteria
US11479588B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2021 |
| Grant date | Oct 25, 2022 |
| Priority date | — |
| Expiry date | Nov 18, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure discloses cathelicidin-expressing lactic acid bacteria, and belongs to the technical field of genetic engineering. The disclosure constructs Lactococcus. lactis and Lactobacillus. plantarum expressing a CRAMP protein by optimizing the nucleotide sequence of the CRAMP protein. The Lactobacillus constructed in the disclosure can be used to prepare a vaccine for regulation of intestinal flora disorder, and has advantages in regulation of intestinal flora and intestinal immune response and maintenance. An anaculture can be directly taken as an oral vaccine to stimulate mice and cause a strong cellular immune response. The recombinant L. lactis can be used as a new oral vaccine product with good industrial prospects, plays a positive role in reducing intestinal inflammation, and has important practical significance for promoting health development of the intestinal tract.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.